Adicet Bio, Inc. (ACET)
| Market Cap | 83.80M +57.0% |
| Revenue (ttm) | n/a |
| Net Income | -116.80M |
| EPS | -16.95 |
| Shares Out | 10.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,647 |
| Open | 8.17 |
| Previous Close | 8.17 |
| Day's Range | 7.81 - 8.17 |
| 52-Week Range | 6.01 - 17.44 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 41.00 (+413.78%) |
| Earnings Date | May 26, 2026 |
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 413.78% from the latest price.
News
Adicet Bio assumed with a Buy at Jefferies
Jefferies assumed coverage of Adicet Bio (ACET) with a Buy rating and a price target of $19, up from $8. Despite early Phase I data with its off-the-shelf allogeneic CD20…
Adicet Bio price target lowered to $27 from $50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Adicet Bio (ACET) to $27 from $50 and keeps a Buy rating on the shares following the Q4 report. The firm cites…
Adicet Bio price target lowered to $100 from $128 at Guggenheim
Guggenheim lowered the firm’s price target on Adicet Bio (ACET) to $100 from $128 and keeps a Buy rating on the shares following the company’s Q4 update. With accelerating enrollment…
Adicet Bio files $250M mixed securities shelf
17:19 EDT Adicet Bio (ACET) files $250M mixed securities shelf
Adicet Bio reports Q4 EPS ($2.94), consensus ($2.99)
Cash, cash equivalents and short-term investments were $158.5 million as of December 31, 2025, compared to $176.3 million as of December 31, 2024. In October 2025, Adicet successfully raised $74.8…
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio price target adjusted to $50 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Adicet Bio (ACET) to $50 from $9 and keeps a Buy rating on the shares. The firm cites the recent reverse stock…
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio price target lowered to $18 from $128 at Canaccord
Canaccord lowered the firm’s price target on Adicet Bio (ACET) to $18 from $128 and keeps a Buy rating on the shares. The firm adjusted its price target to reflect…
Adicet Bio trading halted, news pending
19:50 EST Adicet Bio (ACET) trading halted, news pending
Adicet Bio Announces Reverse Stock Split
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Gamma delta CAR T therapies show strong safety and efficacy in autoimmune diseases, with ongoing responses and immune reset in LN and SLE. Multiple data readouts and regulatory milestones are expected next year, supported by robust manufacturing and a solid cash runway.
Adicet Bio price target raised to $9 from $4 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Adicet Bio (ACET) to $9 from $4 and keeps a Buy rating on the shares. The firm views ADI-001’s…
Adicet Bio reports Q3 EPS , consensus (32c)
“We were pleased to announce positive preliminary data last month from seven SLE and LN patients treated in our Phase 1 trial of ADI-001, underscoring its broad potential as a…
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Transcript: Study Update
Phase 1 results for ADI-001 in LN and SLE showed rapid, durable clinical responses, robust immune reset, and a favorable safety profile, with all patients discontinuing immunosuppressants and most achieving complete or partial renal response. The off-the-shelf, outpatient potential differentiates ADI-001 from autologous therapies, supporting plans for a pivotal single-arm trial in 2026.
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...
Adicet Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Off-the-shelf gamma delta 1 CAR T therapies show strong safety and efficacy in autoimmune diseases, with ADI-001 targeting multiple indications and aiming for outpatient use. Key clinical data are expected this year, and a PSMA-targeted oncology program is advancing.
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...